WithdrawnPhase NA

GLP Analogs for Diabetes in Wolfram Syndrome Patients

Lead sponsor

Hadassah Medical Organization

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Wolfram Syndrome

Eligibility highlights

Primary endpoint

•Beta cell function

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01302327

Org study IDwolfram-HMO-CTIL

Timeline

Milestones

Study first posted2011-02-24estimated

Study start2011-03-01

Primary completion2013-03-01estimated

Study completion2013-03-01actual

Last update posted2022-03-29actual

Assets

Investigational agents

Exenatide

Who this study enrolls

Wolfram Syndrome

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

1. Genetic or definitive clinical diagnosis of Wolfram's syndrome including: diabetes mellitus, optic atrophy and at least one additional neurological dysfunction (diabetes insipidus, sensorineural deafness, neurogenic bladder or other type of autonomic or peripheral neuropathy)

2. Age >18 years

3. Duration of diabetes of <10 years.

Exclusion criteria

1. pregnant women

2. patients who are unable to give inform consent.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint/low confidence

beta cell function

Time frame:3 months

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome.
The Journal of clinical endocrinology and metabolism2016 Oct (month)PMID27459537doi:10.1210/jc.2016-2240via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.